Modern concepts on the role of inflammation in pulmonary fibrosis

Archives of Pathology and Laboratory Medicine

Volumn 135, Issue 6, 2011, Pages 780-788

  Homer, Robert J ^a   Elias, Jack A ^a   Lee, Chun Gun ^a   Herzog, Erica ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; BIOLOGICAL MARKER; CYTOKINE;

ANIMAL; CELL DEATH; DISEASE COURSE; DISEASE MODEL; HUMAN; IMMUNOLOGY; LUNG FIBROSIS; MACROPHAGE; MACROPHAGE ACTIVATION; METABOLISM; MOUSE; PATHOLOGY; PNEUMONIA; REVIEW; TRANSGENIC MOUSE;

ANIMALS; BIOLOGICAL MARKERS; CELL DEATH; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; INFLAMMATION MEDIATORS; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICE, TRANSGENIC; PNEUMONIA; PULMONARY FIBROSIS;

EID: 79958854110     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Review

References (136)

1. Watters LC, King TE, Schwarz MI, Waldron JA, Stanford RE, Cherniack RM. A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis. 1986;133(1):97-103. (Pubitemid 16189105)
2. Selman M, Carrillo G, Estrada A, et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS ONE. 2007;2(5):e482.
3. Liebow AA, Carrington CB. The interstitial pneumonias. In: Simon M, Potchen EJ, LeMay M, eds. Frontiers of Pulmonary Radiology. New York, NY: Grune & Stratton; 1969:102-141.
4. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am) Respir Crit Care Med. 2002;165(2):277-304.
5. Merrill WW, Reynolds HY. Bronchial lavage in inflammatory lung disease. Clin Chest Med. 1983;4(1):71-84. (Pubitemid 13095108)
6. Reynolds HY. Lung inflammation and fibrosis: an alveolar macrophagecentered perspective from the 1970s to 1980s. Am J Respir Crit Care Med. 2005; 171(2):98-102. (Pubitemid 40105406)
7. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med. 2001;345(7):517-525. (Pubitemid 32758505)
8. Noble PW, Homer RJ. Idiopathic pulmonary fibrosis: new insights into pathogenesis. Clin Chest Med. 2004;25(4):749-758. (Pubitemid 39556507)
9. Raghu G, Chang J. Idiopathic pulmonary fibrosis: current trends in management. Clin Chest Med. 2004;25(4):621-636. (Pubitemid 39561702)
10. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001;134(2):136-151. (Pubitemid 32096342)
11. Kuwano K. Involvement of epithelial cell apoptosis in interstitial lung diseases. Intern Med. 2008;47(5):345-353. (Pubitemid 351663683)
12. Katzenstein AL. Pathogenesis of "fibrosis" in interstitial pneumonia: an electron microscopic study. Hum Pathol. 1985;16001:1015-1024.
13. Kuwano K, Hagimoto N, Maeyama T, et al. Mitochondria-mediated apoptosis of lung epithelial cells in idiopathic interstitial pneumonias. Lab Invest. 2002;82(12):1695-1706. (Pubitemid 35462982)
14. Kuwano K, Hagimoto N, Tanaka T, et al. Expression of apoptosisregulatory genes in epithelial cells in pulmonary fibrosis in mice. J Pathol. 2000; 190(2):221-229. (Pubitemid 30082497)
15. Drakopanagiotakis F, Xifteri A, Polychronopoulos V, Bouros D. Apoptosis in lung injury and fibrosis, fur Respir J. 2008;32(6):1631-1638.
16. Kuwano K, Nakashima N, lnoshima I, et al. Oxidative stress in lung epithelial cells from patients with idiopathic interstitial pneumonias. Eur Respir J. 2003;21(2):232-240. (Pubitemid 36204536)
17. Kuwano K, Kawasaki M, Maeyama T, et al. Soluble form of fas and fas ligand in BAL fluid from patients with pulmonary fibrosis and bronchiolitis obliterans organizing pneumonia. Chest. 2000;118(2):451-458. (Pubitemid 30637815)
18. Kuwano K, Hagimoto N, Kawasaki M, et al. Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J Clin Invest. 1999; 104(1):13-19. (Pubitemid 29534340)
19. Kuwano K, Kunitake R, Maeyama T, et al. Attenuation of bleomycininduced pneumopathy in mice by a caspase inhibitor. Am) Physiol Lung Cell Mol Physiol. 2001;280(2):L316-L325.
20. Wang R, Ibarra-Sunga O, Verlinski L, Pick R, Uhal BD. Abrogation of bleomycin-induced epithelial apoptosis and lung fibrosis by Captopril or by a caspase inhibitor. Am J Physiol Lung Cell Mol Physiol. 2000;279(1):L143-L151. (Pubitemid 30619534)
21. Li X, Rayford H, Uhal BD. Essential roles for angiotensin receptor AT1a in bleomycin-induced apoptosis and lung fibrosis in mice. Am J Pathol. 2003; 163(6):2523-2530. (Pubitemid 37466493)
22. Hagimoto N, Kuwano K, Miyazaki H, et al. Induction of apoptosis and pulmonary fibrosis in mice in response to ligation of Fas antigen. Am J Respir Cell Mol Biol. 1997;17(3):272-278. (Pubitemid 127500830)
23. Sisson TH, Mendez M, Choi K, et al. Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. Am J Respir Crit Care Med. 2010; 181(3):254-263.
24. Whitsett JA, Wert SE, Weaver TE. Alveolar surfactant homeostasis and the pathogenesis of pulmonary disease. Annu Rev Med. 2010;61:105-119.
25. Lawson WE, Crossno PF, Polosukhin W, et al. Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: association with altered surfactant protein processing and herpesvirus infection. Am J Physiol Lung Cell Mol Physiol. 2008;294(6):L1119-L1126.
26. Korfei M, Ruppert C, Mahavadi P, et al. Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;178(8):838-846.
27. Chia JY, Jung Y, Liang J, et al. Gene expression profiles and immunohistochemical analysis highlight role of endoplasmic reticulum stress in pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179:A2175.
28. Tsakiri KD, Cronkhite JT, Kuan PJ, et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA. 2007;104(18): 7552-7557. (Pubitemid 47185944)
29. Armanios MY, Chen JJ, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonar/ fibrosis. N Engl J Med. 2007;356(131:1317-1326.
30. Alder JK, Chen JJ, Lancaster L, et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci USA. 2008;105(351:13051- 13056.
31. Cronkhite JT, Xing C, Raghu G, et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;178(71:729-737.
32. Strieter RM. What differentiates normal lung repair and fibrosis?: inflammation, resolution of repair, and fibrosis. Proc Am Thorac Soc. 2008; 5(3):305-310. (Pubitemid 351520676)
33. Kim KK, Wei Y, Szekeres C, et al. Epithelial cell alpha3beta1 integrin links beta-catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis. J Clin Invest. 2009;119(11:213-224.
34. Kim KK, Kugler MC, Wolters PJ, et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci USA. 2006;103(35): 13180-13185. (Pubitemid 44338936)
35. Chilosi M, Zamo A, Doglioni C, et al. Migratory marker expression in fibroblast foci of idiopathic pulmonary fibrosis. Respir Res. 2006;7:95.
36. Willis BC, Liebler JM, Luby-Phelps K, et al. Induction of epithelialmesenchymal transition in alveolar epithelial cells by transforming growth factorbetal : potential role in idiopathic pulmonary fibrosis. Am J Pathol. 2005;166(5): 1321-1332. (Pubitemid 40586504)
37. Douglas IS, Diaz del Valle F, Winn RA, Voelkel NF. Beta-catenin in the fibroproliferative response to acute lung injury. Am) Respir Cell Mol Biol. 2006; 34(3):274-285. (Pubitemid 43320708)
38. Tanjore H, Xu XC, Polosukhin W, et al. Contribution of epithelial-derived fibroblasts to bleomycin-induced lung fibrosis. Am J Respir Crit Care Med. 2009; 180(7):657-665.
39. Chilosi M, Poletti V, Zamo A, et al. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol. 2003;162(5):1495-1502. (Pubitemid 36512831)
40. Wilson MS, Wynn TA. Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol. 2009;2(2):103-121.
41. Lupher MLJ, Gallatin WM. Regulation of fibrosis by the immune system. Adv Immunol. 2006;89:245-288.
42. Martin P, Leibovich SJ. Inflammatory cells during wound repair: the good, the bad and the ugly. Trends Cell Biol. 2005;15(11):599-607. (Pubitemid 41619424)
43. Weaver CT, Murphy KM. T-cell subsets: the more the merrier. Curr Biol. 2007;17(2):R61-R63. (Pubitemid 46107836)
44. Sandor M, Weinstock JV, Wynn TA. Granulomas in schistosome and mycobacterial infections: a model of local immune responses. Trends Immunol. 2003,24(1):44-52. (Pubitemid 35462112)
45. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci. 2008;13:453-461. (Pubitemid 351599757)
46. Tiemessen MM, Jagger AL, Evans HG, van Herwijnen MJ, John S, Taams LS. CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci USA. 2007;104(49):19446-19451.
47. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8(12):958-969.
48. Dominguez PM, Ardavin C. Differentiation and function of mouse monocyte-derived dendritic cells in steady state and inflammation. Immunol Rev. 2010;234(1):90-104.
49. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol. 2004;4(8):583-594.
50. Keane MP, Strieter RM, Lynch JP III, Belperio JA. Inflammation and angiogenesis in fibrotic lung disease. Semin Respir Crit Care Med. 2006;27(6): 589-599. (Pubitemid 46048039)
51. Daley JM, Brancato SK, Thomay AA, Reichner JS, Albina JE. The phenotype of murine wound macrophages. J Leukoc Biol. 2010;87(11:59-67.
52. Duffield JS. The inflammatory macrophage: a story of Jekyll and Hyde. Clin Sci (Lond). 2003;10(2):137-142.
53. Elias JA, Zheng T, Lee CG, et al. Transgenic modeling of interleukin-13 in the lung. Chest. 2003;123(3)(suppl):339S-345S. (Pubitemid 36315401)
54. Wills-Karp M. Interleukin-13 in asthma pathogenesis. Curr Allergy Asthma Rep. 2004;4(2):123-131. (Pubitemid 38906753)
55. Zhu Z, Homer RJ, Wang Z, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999; 103(61:779-788.
56. Zhu Z, Zheng T, Lee CG, Homer RJ, Elias JA. Tetracycline-controlled transcriptional regulation systems: advances and application in transgenic animal modeling. Semin Cell Dev Biol. 2002;13(2):121-128. (Pubitemid 35300824)
57. Homer RJ, Zhu Z, Cohn L, et al. Differential expression of chitinases identify subsets of murine airway epithelial cells in allergic inflammation. Am J Physiol Lung Cell Mol Physiol. 2006;291 (3):L502-L511. (Pubitemid 44343728)
58. Homer RJ, Zheng T, Chupp G, et al. Pulmonary type II cell hypertrophy and pulmonary lipoproteinosis are features of chronic IL-13 exposure. Am J Physiol Lung Cell Mol Physiol. 2002;283(1):L52-L59. (Pubitemid 34764541)
59. Zheng T, Zhu Z, Wang Z, et al. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J Clin Invest. 2000;106(9):1081-1093.
60. Lee JH, Kaminski N, Dolganov G, et al. Interleukin-13 induces dramatically different transcriptional programs in three human airway cell types. Am J Respir Cell Mol Biol. 2001;25(4):474-485. (Pubitemid 33037680)
61. Zhu Z, Ma B, Zheng T, et al. IL-13-induced chemokine responses in the lung: role of CCR2 in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol. 2002;168(6):2953-2962. (Pubitemid 34211676)
62. Quan TE, Cowper S, Wu SP, Bockenstedt LK, Bucala R. Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol. 2004;36(4):598-606. (Pubitemid 38316817)
63. Moore BB, Kolodsick JE, Thannickal VJ, et al. CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am J Pathol. 2005;166(3): 675-684. (Pubitemid 40315625)
64. Moore BB. Fibrocytes as potential biomarkers in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179(7):524-525.
65. Ma B, Zhu Z, Homer RJ, Gerard C, Strieter R, Elias JA. The C10/CCL6 chemokine and CCR1 play critical roles in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol. 2004;172(3):1872-1881. (Pubitemid 38116837)
66. Ma B, Liu W, Homer RJ, et al. Role of CCR5 in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol. 2006,-176(8):4968-4978.
67. Lee CG, Hartl D, Matsuura H, et al. Endogenous IL-11 signaling is essential in Th2- and IL-13-induced inflammation and mucus production. Am J Respir Cell Mol Biol. 2008;39(6):739-746.
68. Fulkerson PC, Fischetti CA, Rothenberg ME. Eosinophils and CCR3 regulate interleukin-13 transgene-induced pulmonary remodeling. Am J Pathol. 2006;169(6):2117-2126. (Pubitemid 351181971)
69. Jakubzick C, Choi ES, Kunkel SL, Joshi BH, Puri RK, Hogaboam CM. Impact of interleukin-13 responsiveness on the synthetic and proliferative properties of Th1- and Th2-type pulmonary granuloma fibroblasts. Am) Pathol. 2003;162(5):1475-1486.
70. Kolodsick JE, Toews GB, Jakubzick C, et al. Protection from fluorescein isothiocyanate-induced fibrosis in IL-13-deficient, but not IL-4-deficient, mice results from impaired collagen synthesis by fibroblasts. J Immunol. 2004;172(7): 4068-4076. (Pubitemid 38375218)
71. Blackburn MR, Lee CG, Young HW, et al. Adenosine mediates IL-13induced inflammation and remodeling in the lung and interacts in an IL-13adenosine amplification pathway. J Clin Invest. 2003;112(31:332-344.
72. Chunn JL, Mohsenin A, Young HW, et al. Partially adenosine deaminasedeficient mice develop pulmonar/ fibrosis in association with adenosine elevations. Am J Physiol Lung Cell Mol Physiol. 2006;290(3):L579-L587. (Pubitemid 43725103)
73. Gangadharan B, Hoeve MA, Allen JE, et al. Murine gammaherpesvirusinduced fibrosis is associated with the development of alternatively activated macrophages.; Leukoc Biol. 2008;84(1):50-58. (Pubitemid 351960279)
74. Shimamura T, Fujisawa T, Husain SR, Kioi M, Nakajima A, Puri RK. Novel role of IL-13 in fibrosis induced by nonalcoholic steatohepatitis and its amelioration by IL-13R-directed cytotoxin in a rat model. J Immunol. 2008; 181(7):4656-4665.
75. Fichtner-Feigl S, Young CA, Kitani A, Geissler EK, Schlitt HJ, Strober W. IL13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis. Gastroenterology. 2008;135(6):2003-2013.
76. Fichtner-Feigl S, Fuss IJ, Young CA, et al. Induction of IL-13 triggers TGFbetal -dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis.) Immunol. 2007;178(9):5859-5870. (Pubitemid 46674383)
77. Belperio JA, Dy M, Burdick MD, et al. Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2002;27(4):419-427.
78. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med. 2006;12(1):99-106. (Pubitemid 43050083)
79. Jakubzick C, Choi ES, Joshi BH, et al. Therapeutic attenuation of pulmonary fibrosis via targeting of IL-4- and IL-13-responsive cells. J Immunol. 2003;171 (5):2684-2693. (Pubitemid 37025582)
80. Lewis CC, Yang JY, Huang X, et al. Disease-specific gene expression profiling in multiple models of lung disease. Am J Respir Crit Care Med. 2008; 177(4):376-387. (Pubitemid 351317580)
81. Wilson MS, Madala SK, Ramalingam TR, et al. Bleomycin and IL-I betamediated pulmonar/ fibrosis is IL-17A dependent. J Exp Med. 2010;207(3):535-552.
82. Liu T, Jin H, Ullenbruch M, et al. Regulation of found in inflammatory zone 1 expression in bleomycin-induced lung fibrosis: role of IL-4/IL-13 and mediation via STAT-6. J Immunol. 2004; 173(5):3425-3431. (Pubitemid 39142053)
83. Jiang D, Liang J, Hodge J, et al. Regulation of pulmonary fibrosis by chemokine receptor CXCR3. J Clin Invest. 2004;114(2):291-299. (Pubitemid 39071634)
84. Murray LA, Rosada R, Moreira AP, et al. Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. PLoS One. 2010;5(3):e9683.
85. Wallace WA, Ramage EA, Lamb D, Howie SE. A type 2 (Th2-like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis (CFA). Clin Exp Immunol. 1995;101(3):436-441.
86. Xiao L, Li ZH, Hou XM, Yu RJ. Evaluation of interleukin-13 in the serum and bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis [in Chinese]. Zhongbua lie He He Hu Xi Za Zhi 2003;26(11):686-688.
87. Wallace WA, Howie SE. Immunoreactive interleukin 4 and interferongamma expression by type Il alveolar epithelial cells in interstitial lung disease. J Pathol. 1999;187(4):475-480. (Pubitemid 29118281)
88. Hancock A, Armstrong L, Gama R, Millar A. Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am J Respir Cell Mol Biol. 1998;18(1):60-65.
89. Golee M, Lambers C, Hofbauer E, et al. Assessment of gene transcription demonstrates connection with the clinical course of idiopathic interstitial pneumonia. Respiration. 2008;76(3):261-269.
90. Voehringer D, Reese TA, Huang X, Shinkai K, Locksley RM. Type 2 immunity is controlled by IL-4/IL-13 expression in hematopoietic non-eosinophil cells of the innate immune system. J Exp Med. 2006;203(6):1435-1446. (Pubitemid 43877606)
91. Kim EY, Battaile JT, Patel AC, et al. Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. Nat Med. 2008; 14(6):633-640. (Pubitemid 351809546)
92. Arora M, Chen L, Paglia M, et al. Simvastatin promotes Th2-type responses through the induction of the chitinase family member Ym1 in dendritic cells. Proc Natl Acad Sci USA. 2006;103(20):7777-7782.
93. Temann UA, Laouar Y, Eynon EE, Homer R, Flavell RA. IL9 leads to airway inflammation by inducing IL13 expression in airway epithelial cells. Int Immunol. 2007;1901:1-10.
94. Allahverdian S, Harada N, Singhera GK, Knight DA, Dorscheid DR. Secretion of IL-13 by airway epithelial cells enhances epithelial repair via HBEGF. Am J Respir Cell Mol Biol. 2008;38(2):153-160. (Pubitemid 351162836)
95. Razonable RR, Henault M, Paya CV. Stimulation of toll-like receptor 2 with bleomycin results in cellular activation and secretion of pro-inflammatory cytokines and chemokines. Toxicol Appl Pharmacol. 2006;210(3):181-189. (Pubitemid 43107561)
96. Redecke V, Hacker H, Datta SK, et al. Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma. J Immunol. 2004;172(5):2739-2743. (Pubitemid 38263655)
97. Matsushita M, Yamamoto T, Nishioka K. Upregulation of interleukin-13 and its receptor in a murine model of bleomycin-induced scleroderma. Int Arch Allergy Immunol. 2004;135(4):348-356. (Pubitemid 40082202)
98. Lakos G, Melichian D, Wu M, Varga J. Increased bleomycin-induced skin fibrosis in mice lacking the ThI-specific transcription factor T-bet. Pathobiology. 2006;73(5):224-237. (Pubitemid 46332830)
99. Aliprantis AO, Wang J, Fathman JW, et al. Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proc Natl Acad Sci USA. 2007;104(8):2827-2830. (Pubitemid 46327964)
100. Wills-Karp M, Finkelman FD. Untangling the complex web of IL-4- and IL-13-mediated signaling pathways. Sci Signal. 2008;1(51):pe55.
101. Zheng T, Zhu Z, Liu W, et al. Cytokine regulation of IL-13Ralpha2 and IL13Ralpha1 in vivo and in vitro. J Allergy Clin Immunol. 2003;111 (4):720-728. (Pubitemid 36470239)
102. Jakubzick C, Choi ES, Carpenter KJ, et al. Human pulmonary fibroblasts exhibit altered interleukin-4 and interleukin-13 receptor subunit expression in idiopathic interstitial pneumonia. Am J Pathol. 2004;164(6):1989-2001. (Pubitemid 38669348)
103. Jakubzick C, Choi ES, Kunkel SL, et al. Augmented pulmonary IL-4 and IL-13 receptor subunit expression in idiopathic interstitial pneumonia. J Clin Pathol. 2004;57(5):477-486. (Pubitemid 38621792)
104. Murray LA, Argentieri RL, Farrell FX, et al. Hyper-responsiveness of IPF/ UIP fibroblasts: interplay between TGFbetal, IL-13 and CCL2. Int J Biochem Cell Biol. 2008;40(10):2174-2182.
105. Pardo A, Smith KM, Abrams J, et al. CCLI8/DC-CK-1/PARC up-regulation in hypersensitivity pneumonitis. J Leukoc Biol. 2001;70(4):610-616.
106. Schutyser E, Richmond A, Van Damme J. Involvement of CC chemokine ligand 18 (CCLI 8) in normal and pathological processes. J Leukoc Biol. 2005; 78(11:14-26.
107. Kodera M, Hasegawa M, Komura K, Yanaba K, Takehara K, Sato S. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis. Arthritis Rheum. 2005;52(9):2889-2896. (Pubitemid 41369120)
108. Prasse A, Pechkovsky DV, Toews GB, et al. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am I Respir Crit Care Med. 2006;173(7):781-792.
109. Prasse A, Pechkovsky DV, Toews GB, et al. CCLI8 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum. 2007;56(5):1685-1693. (Pubitemid 46764100)
110. Prasse A, Probst C, Bargagli E, et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179(8):717-723.
111. Mathai SK, Gulati M, Peng X, et al. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Lab Invest. 2010;90(6):812-823.
112. Woodruff PG, Boushey HA, Dolganov GM, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci USA. 2007; 104(40): 15858-15863. (Pubitemid 350035389)
113. Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180(5):388-395.
114. Jia G, Modrek B, Choy DF, Abbas AR, Woodruff PG, Fahy JV. Peripheral biomarkers of an IL-13 induced bronchial epithelial gene signature in asthma. Poster presented at: Asthma and Allergy Keystone Symposium; January 18-20, 2009; Keystone, CO.
115. Milano A, Pendergrass SA, Sargent JL, et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One. 2008;3(7):e2696.
116. Sargent JL, Milano A, Bhattacharyya S, et al. A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol. 2010; 130(31:694-705.
117. Khalil N, Greenberg AH. The role of TGF-beta in pulmonary fibrosis. Ciba Found Symp. 1991;157:194-207.
118. Letterio JJ, Roberts AB. Transforming growth factor-betal -deficient mice: identification of isoform-specific activities in vivo. J Leukoc Biol. 1996;59(6): 769-774. (Pubitemid 26238470)
119. Lee CG, Homer RJ, Zhu Z, et al. lnterleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med. 2001,-194(6):809-821.
120. Kaviratne M, Hesse M, Leusink M, et al. IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J Immunol. 2004;173(6): 4020-4029. (Pubitemid 39280766)
121. Lee CG, Cho SJ, Kang MJ, et al. Early growth response gene 1-mediated apoptosis is essential for transforming growth factor betai-induced pulmonary fibrosis. J Exp Med. 2004;200(3):377-389. (Pubitemid 39031256)
122. Kang HR, Cho SJ, Lee CG, Homer RJ, Elias JA. Transforming growth factor (TGF)-betal stimulates pulmonary fibrosis and inflammation via a Baxdependent, bid-activated pathway that involves matrix metalloproteinase-12. J Biol Chem. 2007;282(101:7723-7732.
123. Kang HR, Lee CG, Homer RJ, Elias JA. Semaphorin 7A plays a critical role in TGF-beta1-induced pulmonary fibrosis. J Exp Med. 2007;204(5):1083-1093. (Pubitemid 46798152)
124. Yamasaki M, Kang HR, Homer RJ, et al. P21 regulates TGF-beta1induced pulmonary responses via a TNF-alpha-signaling pathway. Am J Respir Cell Mol Biol. 2008;38(3):346-353. (Pubitemid 351567704)
125. Wang Z, Zheng T, Zhu Z, et al. Interferon gamma induction of pulmonary emphysema in the adult murine lung. J Exp Med. 2000;192(11):1587-1600.
126. Chapoval SP, Al-Garawi A, Lora JM, et al. Inhibition of NF-kappaB activation reduces the tissue effects of transgenic IL-13J Immunol. 2007;179(10): 7030-7041.
127. Cho SJ, Kang MJ, Homer RJ, et al. Role of early growth response-1 (Egr-1 J in interleukin-13-induced inflammation and remodeling. J Biol Chem. 2006; 281(12):8161-8168. (Pubitemid 43847435)
128. Lee CG, Hartl D, Lee GR, et al. Role of breast regression protein 39 (BRP39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J Exp Med. 2009;206(5):1149-1166.
129. Pulichino AM, Wang IM, Caron A, et al. Identification of transforming growth factor betai -driven genetic programs of acute lung fibrosis. Am J Respir Cell Mol Biol. 2008;39(3):324-336.
130. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature. 1997;390(6658):350-351.
131. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGFbeta, PGE2, and PAF. J Clin Invest. 1998;101 (4):890-898. (Pubitemid 28096086)
132. Nacu N, Luzina IG, Highsmith K, et al. Macrophages produce TGF-betainduced (beta-ig-h3) following ingestion of apoptotic cells and regulate MMPI4 levels and collagen turnover in fibroblasts. J Immunol. 2008; 180(71:5036-5044.
133. Medeiros Al, Serezani CH, Lee SP, Peters-Golden M. Efferocytosis impairs pulmonary macrophage and lung antibacterial function via PGE2/EP2 signaling.; Exp Med. 2009;20601:61-68.
134. Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation and immunity. Cell. 2010;140(6):798-804.
135. Gratchev A, Kzhyshkowska J, Kannookadan S, et al. Activation of a TGFbeta-specific multistep gene expression program in mature macrophages requires glucocorticoid-mediated surface expression of TGF-beta receptor II. J Immunol. 2008;180(101:6553-6565.
136. King TEJ, Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet. 2009;374(9685):222- 228.